ATE371649T1 - Pyridazinonharnstoffe als antagonisten von a4- integrinen - Google Patents
Pyridazinonharnstoffe als antagonisten von a4- integrinenInfo
- Publication number
- ATE371649T1 ATE371649T1 AT05722893T AT05722893T ATE371649T1 AT E371649 T1 ATE371649 T1 AT E371649T1 AT 05722893 T AT05722893 T AT 05722893T AT 05722893 T AT05722893 T AT 05722893T AT E371649 T1 ATE371649 T1 AT E371649T1
- Authority
- AT
- Austria
- Prior art keywords
- pyridazinone
- integrins
- ureas
- antagonists
- pyridazinone ureas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54331504P | 2004-02-10 | 2004-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE371649T1 true ATE371649T1 (de) | 2007-09-15 |
Family
ID=34860402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05722893T ATE371649T1 (de) | 2004-02-10 | 2005-02-09 | Pyridazinonharnstoffe als antagonisten von a4- integrinen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050209232A1 (de) |
| EP (1) | EP1725538B1 (de) |
| JP (1) | JP2007522224A (de) |
| KR (1) | KR20070001976A (de) |
| CN (1) | CN1946699A (de) |
| AR (1) | AR047537A1 (de) |
| AT (1) | ATE371649T1 (de) |
| AU (1) | AU2005212423A1 (de) |
| BR (1) | BRPI0506676A (de) |
| CA (1) | CA2555227A1 (de) |
| DE (1) | DE602005002251D1 (de) |
| MX (1) | MXPA06009099A (de) |
| WO (1) | WO2005077914A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070010450A1 (en) | 2003-06-13 | 2007-01-11 | Microbia, Inc., A Massachusetts Corporation | Methods and compositions for the treatment of gastrointestinal disorders |
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| TWI375669B (en) | 2006-03-17 | 2012-11-01 | Sumitomo Chemical Co | Pyridazinone compound and use thereof |
| JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| JP5431305B2 (ja) | 2007-04-23 | 2014-03-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体 |
| WO2008128996A1 (en) | 2007-04-23 | 2008-10-30 | Janssen Pharmaceutica N.V. | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
| CL2008002703A1 (es) | 2007-09-14 | 2009-11-20 | Sumitomo Chemical Co | Compuestos derivados de 1,4-dihidro-2h-piridazin-3-ona; composicion herbicida que comprende a dichos compuestos; metodo de control de malezas; uso de dichos compuestos para el control de malezas; y compuestos intermediarios. |
| EP2307374B1 (de) | 2008-07-31 | 2017-01-25 | Janssen Pharmaceutica NV | Piperazin-1-yl-trifluoromethyl-substituierte-pyridine als schnell dissoziierende dopamin 2-rezeptorantagonisten |
| EP2424841A1 (de) * | 2009-04-27 | 2012-03-07 | Elan Pharmaceuticals Inc. | Pyridinonantagonisten von alpha-4-integrinen |
| WO2010151672A2 (en) * | 2009-06-26 | 2010-12-29 | Georgetown University | Amino acid derived ureas |
| WO2012113103A1 (en) * | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| CA3017048C (en) | 2016-03-22 | 2023-11-07 | Helsinn Healthcare Sa | Benzenesulfonyl-asymmetric ureas and medical uses thereof |
| US10906874B2 (en) | 2016-09-18 | 2021-02-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | YAP1 inhibitors that target the interaction of YAP1 with OCT4 |
| US12582809B2 (en) | 2018-01-26 | 2026-03-24 | Bt Bidco, Inc. | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor |
| MX2020009519A (es) | 2018-03-14 | 2020-10-22 | H Lee Moffitt Cancer Ct & Res | Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4. |
| EP3810085A1 (de) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Behandlung der erkrankung des gastrointestinaltraktes mit einem integrin-inhibitor |
| KR102630416B1 (ko) | 2018-10-30 | 2024-02-01 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
| CN114222730B (zh) | 2019-08-14 | 2024-09-10 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3905971A (en) * | 1971-03-29 | 1975-09-16 | Pfizer | 2-Phenyl-as-triazine-3,5(2H,4H)diones |
| IE62890B1 (en) * | 1988-12-06 | 1995-03-08 | Hafslund Nycomed Pharma | New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure |
| US6090785A (en) * | 1992-10-15 | 2000-07-18 | Merck & Co., Inc. | Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents |
| US5525623A (en) * | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| US5827860A (en) * | 1995-06-07 | 1998-10-27 | Ortho Pharmaceutical Corporation | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
| US5827866A (en) * | 1995-06-07 | 1998-10-27 | Ortho Pharmaceutical Corporation | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
| US5523308A (en) * | 1995-06-07 | 1996-06-04 | Costanzo; Michael J. | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
| US6291511B1 (en) * | 1997-05-29 | 2001-09-18 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
| US6221888B1 (en) * | 1997-05-29 | 2001-04-24 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
| US6229011B1 (en) * | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
| US6455550B1 (en) * | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
| NZ503407A (en) * | 1997-10-31 | 2002-08-28 | Aventis Pharma Ltd | Anilide derivatives useful for treating inflammatory diseases |
| US6191171B1 (en) * | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
| MY153569A (en) * | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| KR100657189B1 (ko) * | 1998-08-14 | 2006-12-14 | 니혼노야쿠가부시키가이샤 | 피리다지논 유도체 및 이를 함유하는 의약 조성물 |
| US6436904B1 (en) * | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6407066B1 (en) * | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| HUP0201295A3 (en) * | 1999-01-27 | 2002-10-28 | Ortho Mcneil Pharm Inc | Peptidyl heterocyclic ketones useful as tryptase inhibitors |
| KR100649819B1 (ko) * | 1999-02-18 | 2007-02-28 | 에프. 호프만-라 로슈 아게 | 티오아미드 유도체 |
| CA2361162A1 (en) * | 1999-03-01 | 2000-09-08 | Elan Pharmaceuticals, Inc. | Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7-receptor antagonists |
| AU6903200A (en) * | 1999-08-16 | 2001-03-13 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
| AU6909300A (en) * | 1999-08-20 | 2001-03-19 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
| US20030130166A1 (en) * | 1999-08-24 | 2003-07-10 | Sonia Cunningham | Polynucleotide encoding a human junctional adhesion protein (JAM2) |
| US6534513B1 (en) * | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
| US6388084B1 (en) * | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
| US6380387B1 (en) * | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| US6849639B2 (en) * | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
| JP2003517023A (ja) * | 1999-12-16 | 2003-05-20 | バイオジェン インコーポレイテッド | 中枢神経系の虚血性損傷または出血性損傷を、抗α４インテグリンアンタゴニストを用いて処置する方法 |
| EA004673B1 (ru) * | 1999-12-28 | 2004-06-24 | Пфайзер Продактс Инк. | Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний |
| US6579889B2 (en) * | 2000-06-22 | 2003-06-17 | Merck & Co., Inc. | Substituted isonipecotyl derivatives as inhibitors of cell adhesion |
| US6403584B1 (en) * | 2000-06-22 | 2002-06-11 | Merck & Co., Inc. | Substituted nipecotyl derivatives as inhibitors of cell adhesion |
| US6960597B2 (en) * | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| US7015216B2 (en) * | 2000-07-21 | 2006-03-21 | Elan Pharmaceuticals, Inc. | Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors |
| GB0028844D0 (en) * | 2000-11-27 | 2001-01-10 | Celltech Chiroscience Ltd | Chemical compounds |
| US6559174B2 (en) * | 2001-03-20 | 2003-05-06 | Merck & Co., Inc. | N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors |
-
2005
- 2005-02-09 DE DE602005002251T patent/DE602005002251D1/de not_active Expired - Lifetime
- 2005-02-09 AR ARP050100450A patent/AR047537A1/es unknown
- 2005-02-09 CA CA002555227A patent/CA2555227A1/en not_active Abandoned
- 2005-02-09 AT AT05722893T patent/ATE371649T1/de not_active IP Right Cessation
- 2005-02-09 WO PCT/US2005/004181 patent/WO2005077914A1/en not_active Ceased
- 2005-02-09 US US11/054,175 patent/US20050209232A1/en not_active Abandoned
- 2005-02-09 MX MXPA06009099A patent/MXPA06009099A/es not_active Application Discontinuation
- 2005-02-09 BR BRPI0506676-0A patent/BRPI0506676A/pt not_active Application Discontinuation
- 2005-02-09 JP JP2006553219A patent/JP2007522224A/ja not_active Withdrawn
- 2005-02-09 AU AU2005212423A patent/AU2005212423A1/en not_active Abandoned
- 2005-02-09 KR KR1020067017323A patent/KR20070001976A/ko not_active Withdrawn
- 2005-02-09 EP EP05722893A patent/EP1725538B1/de not_active Expired - Lifetime
- 2005-02-09 CN CNA2005800121490A patent/CN1946699A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR047537A1 (es) | 2006-01-25 |
| CA2555227A1 (en) | 2005-08-25 |
| JP2007522224A (ja) | 2007-08-09 |
| KR20070001976A (ko) | 2007-01-04 |
| EP1725538B1 (de) | 2007-08-29 |
| BRPI0506676A (pt) | 2007-05-15 |
| AU2005212423A1 (en) | 2005-08-25 |
| WO2005077914A1 (en) | 2005-08-25 |
| MXPA06009099A (es) | 2007-02-02 |
| EP1725538A1 (de) | 2006-11-29 |
| CN1946699A (zh) | 2007-04-11 |
| US20050209232A1 (en) | 2005-09-22 |
| DE602005002251D1 (de) | 2007-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE440095T1 (de) | Benzimidazolderivate und ihre verwendung als aii rezeptor-antagonist | |
| ATE409182T1 (de) | Tetrahydrochinolinone und deren verwendung als antagonisten von metabotropen glutamatrezeptoren | |
| ATE420557T1 (de) | Verwendung von sulfonylharnstoffen | |
| ATE413400T1 (de) | Cgrp-rezeptorantagonisten | |
| DE602005002251D1 (de) | Pyridazinonharnstoffe als antagonisten von a4-integrinen | |
| ATE520672T1 (de) | Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine | |
| ATE414074T1 (de) | 2-oxo-1,2,4,5-tetrahydro-1,3-benzdiazepin-3-yl- piperidine als cgrp-antagonisten | |
| ATE473214T1 (de) | 2-(4-oxo-4h-chinazolin-3-yl)acetamide und ihre verwendung als vasopressin-v3-antagonisten | |
| DE602007010269D1 (de) | Synthese von acylaminoalkenylenamiden als substanz-p-antagonisten | |
| ATE494285T1 (de) | Muscarinische acetylcholin-rezeptor-antagonisten | |
| ATE441639T1 (de) | 2,4-diamino-pyrimidine als aurora inhibitoren | |
| ATE544758T1 (de) | Carboxamidverbindungen und ihre verwendung als calpain-hemmer | |
| ATE481099T1 (de) | Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten | |
| DE602007009305D1 (de) | Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors | |
| ATE450526T1 (de) | Als antagonisten von histamin h3 geeignete piperidinderivate | |
| ATE471938T1 (de) | Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten | |
| ATE512966T1 (de) | Pyrazolo-pyrimidin-derivate als mglur2- antagonisten | |
| ATE417045T1 (de) | Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten | |
| ATE445399T1 (de) | Pyridyl-derivate und ihre verwendung als mglu5- rezeptorantagonisten | |
| ATE518834T1 (de) | 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten | |
| DE112005000151A5 (de) | Verwendung von Kern-Mantel-Partikeln | |
| DE60316411D1 (de) | Thiazolderivate als npy-rezeptorantagonisten | |
| ATE396185T1 (de) | Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten | |
| ATE486070T1 (de) | Piperidinylaminopyridazine und ihre verwendung als schnelldissoziierende antagonisten des dopamin-2-rezeptors | |
| ATE537144T1 (de) | Nitrierte heterocyclische verbindungen als endothelinrezeptorantagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |